ACT for Liver Disease in India: Hepatic Regenerative Support at the Cellular Level | ALIV

Medically Reviewed by Dr. Sunita Tandulwadkar | Written by ALIV

The liver's extraordinary natural regenerative capacity — it can regenerate from as little as 25% of its original mass — makes it one of the most biologically receptive organs to regenerative medicine approaches. Yet in advanced chronic liver disease, this regenerative capacity is overwhelmed by the fibrotic and inflammatory environment, the loss of functional hepatocyte mass, and the exhaustion of resident liver progenitor cells. ALIV's ACT programme for liver conditions aims to supplement this depleted regenerative environment with a concentrated paracrine signal that supports hepatocyte survival, reduces hepatic inflammation, and modulates the fibrogenic process.

The Growth Factor Rationale in Liver ACT

The key growth factor for hepatic regenerative medicine is HGF — Hepatocyte Growth Factor. HGF is the primary mitogenic signal for hepatocytes and is produced physiologically in response to liver injury as part of the normal hepatic repair response. In chronic liver disease, HGF production is insufficient to overcome the chronic inflammatory and fibrogenic pressure. ACT preparations — particularly bone marrow derived — are relatively rich in HGF alongside TGF-β regulatory signals that can modulate the fibrogenic process (hepatic stellate cell activation into myofibroblasts is the driver of fibrosis; TGF-β signalling in ACT preparations can modulate this activation). VEGF supports hepatic angiogenesis — restoration of the sinusoidal blood supply that is disrupted in cirrhotic liver architecture. The combined paracrine effect aims to shift the liver microenvironment from progressive fibrosis toward stabilisation and limited regeneration of functional hepatocyte mass.

Conditions and Staging

ALIV's liver ACT programme is most appropriate for: chronic liver disease due to NAFLD/MASLD at fibrosis stage F2–F3 (significant but not end-stage fibrosis); compensated cirrhosis (Child-Pugh A or early B) without significant portal hypertension complications; alcoholic liver disease in patients who have achieved sustained abstinence; and autoimmune liver conditions that have reached a therapeutic plateau on standard immunosuppression. End-stage liver disease (Child-Pugh C, decompensated cirrhosis with ascites, hepatic encephalopathy, or variceal bleeding) is not an appropriate ACT indication — these patients require hepatology and transplant evaluation. See: liver health and fatty liver — the complete guide for context on disease staging.

Can ACT reverse cirrhosis?

Reversal of established cirrhosis is not a realistic clinical expectation from current ACT protocols. What is achievable is stabilisation of the fibrotic process, meaningful improvement in hepatic synthetic function markers (albumin, clotting factors), reduction in hepatic inflammation (improved ALT, AST, GGT), and improved patient wellbeing (reduced fatigue, improved appetite). Some patients show modest improvement in Child-Pugh score over six to twelve months post-ACT. Meaningful reversal of advanced cirrhosis requires a level of structural remodelling that current paracrine approaches cannot achieve — this is an honest clinical statement, not a limitation unique to ALIV's programme.

How is ACT administered for liver conditions?

Liver ACT at ALIV typically involves intravenous administration of the processed cell preparation — the hepatic portal circulation delivers the growth factors to the liver via the systemic venous system. In some protocols, targeted hepatic arterial administration under imaging guidance is used for more direct liver delivery. The specific administration route for each patient's protocol is determined by the clinical team based on the patient's hepatic anatomy, disease stage, and comorbidities.

Should ACT replace my hepatologist's management for liver disease?

No — ACT is explicitly adjunctive to hepatology management, not a replacement for it. Patients with liver disease should maintain regular hepatology follow-up throughout and after the ACT programme. This includes monitoring for complications of chronic liver disease (hepatocellular carcinoma surveillance, portal hypertension assessment), management of comorbidities (diabetes, dyslipidaemia), and any antiviral therapy where relevant (hepatitis B or C). ALIV works alongside the hepatologist's management plan, never in competition with it.

Medically Reviewed by Dr. Sunita Tandulwadkar. This article is for informational purposes only and does not constitute medical advice. Therapies offered by ALIV are proprietary, experimental protocols and results vary by individual.